Infliximab and rate of adverse events
in COVID-19
patients:
The rate of adverse events was not statistically significant between the
two groups according to our study.
According to Hernandez et. al., meta-analysis, the adverse effects of
monoclonal antibodies on hospitalized patients with COVID-19 was
uncertain (RR 1.31; 95% CI, 1.02-1.67; I2 = 77%). In non-hospitalized
patients, monoclonal antibodies could marginally decrease the serious
adverse events (RR 0.47; 95% CI, 0.22-1.01; I2 = 33%) [24]. The
risk of any adverse events (OR, 0.90; 95% CI: 0.79–1.03; p = 0.14) and
drug-related adverse events (OR, 1.43; 95% CI: 0.85–2.41; p = 0.18) in
the three groups of non-hospitalized patients with COVID-19 managed by
nirmatrelvir plus ritonavir, remdesivir, and molnupiravir were similar
to placebo counterparts based on Lai et. al., meta-analysis [25].